Cero therapeutics holdings, inc. regains compliance with nasdaq listing rule 5550(b)(1)

South san francisco, calif., may 08, 2025 (globe newswire) -- cero therapeutics holdings, inc., (nasdaq: cero) (“cero” or the “company”) an innovative immunotherapy company seeking to advance the next generation of engineered t cell therapeutics that employ phagocytic mechanisms, announces it has regained compliance with nasdaq listing rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million (the “equity rule”)
NDAQ Ratings Summary
NDAQ Quant Ranking